European Medicines Agency Recommends Eli Lilly's Foundayo for Weight Management and Type 2 Diabetes

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-16
Category: health
Source: European Medicines Agency / Reuters / Pink Sheet
Original source

The European Medicines Agency's CHMP has recommended approval for Eli Lilly's oral GLP-1 receptor agonist, Foundayo (orforglipron). This once-daily pill is intended for adult weight management and type 2 diabetes treatment. The recommendation positions Foundayo as a new oral alternative to existing injectable and other oral GLP-1 receptor agonists.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai